Trials / Completed
CompletedNCT05324436
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Special Drug Use Investigation (Survey) of Yervoy and Opdivo Combination Therapy in Patients With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 75 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).
Conditions
Timeline
- Start date
- 2022-01-08
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2022-04-12
- Last updated
- 2025-01-20
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05324436. Inclusion in this directory is not an endorsement.